Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Ann Horowitz"'
Autor:
Diana Montgomery, Anish Mehta, Elisabeth Riedl, Christine Bangert, Ann Horowitz, Frank van Aarle, Tamara Kopp, Xiaoli Shirley Hou, Elli K. Greisenegger, Sauzanne Khalilieh, Thomas Marbury, Wendy M. Blumenschein, Anthe S. Zandvliet, Edward P. Bowman, Claus Zachariae, Danlin Xu, Harald Kittler, Terrill K. McClanahan
Publikováno v:
Nature. 521:222-226
A proof-of-concept phase I clinical trial demonstrates that targeting interleukin (IL)-23 with an antibody that binds to the p19 subunit leads to clinical improvement of disease in patients with moderate to severe psoriasis. Sauzanne Khalilieh and co
Publikováno v:
Drug development and industrial pharmacy. 43(7)
A new improved mometasone furoate (Elocon™) cream with an emulsification system that produces a stable emulsion has been developed. In order to register the product in various markets, it was essential to ensure the cream was topically well tolerat
Autor:
Paula A. Schneider, David A. Parry, Brian M. Thomas, Tomoko Freshwater, Steven D. Gore, Judith E. Karp, Douglas E. Gladstone, Margaret M. Showel, Scott H. Kaufmann, Karen Mackey, Randi Isaacs, Hetty E. Carraway, B. Douglas Smith, Jacqueline Greer, Kevin A. Peterson, Sabine Loechner, Michael A. McDevitt, Keith W. Pratz, Mark J. Levis, Christopher Sorge, Karen S. Flatten, Jo Ann Horowitz
Publikováno v:
Clinical Cancer Research. 18:6723-6731
Purpose: Incorporation of cytarabine into DNA activates checkpoint kinase 1 (Chk1), which stabilizes stalled replication forks, induces S-phase slowing, and diminishes cytarabine cytotoxicity. The selective Chk1 inhibitor SCH 900776 abrogates cytarab
Autor:
Anish Mehta, Tamara Kopp, Elisabeth Riedl, Christine Bangert, Edward Bowman, Elli Greisenegger, Ann Horowitz, Harald Kittler, Wendy Blumenschein, Terrill McClanahan, Thomas Marbury, Claus Zachariae, Danlin Xu, Xiaoli (Shirley) Hou, Anthe Zandvliet, Diana Montgomery, Frank van Aarle, Sauzanne Khalilieh
Publikováno v:
Protocol Exchange.
Autor:
Ann Horowitz, Christine Xu, Diana Montgomery, Marianne van Vugt, Shirley Glasgow, Joanne Marjason, Anish Mehta, Sauzanne Khalilieh, Anthe S. Zandvliet
Publikováno v:
International journal of clinical pharmacology and therapeutics. 53(2)
Objective To evaluate the effect of ethnicity on the pharmacokinetics (PK) of tildrakizumab, a novel anti-IL-23 monoclonal antibody for the treatment of psoriasis. Materials and methods This was an open-label, 2-part study in healthy adult subjects.
Autor:
Stephen R. Indelicato, Shu Fen Wen, Jeremy Shinoda, I A Atencio, Alan P. Venook, Daniel C. Maneval, Mary Lynn Musco, Robert S. Warren, Beth Hutchins, Ronald Bordens, Grace Michael, M Fritz, Karen Kolz, Sheila Jacobs, Jo Ann Horowitz
Publikováno v:
Cancer Gene Therapy. 13:169-181
The major focus of intrahepatic arterial (IHA) administration of adenoviruses (Ad) has been on safety. Currently, there is little published data on the biological responses to Ad when administered via this route. As part of a Phase I study, we evalua
Publikováno v:
Pulmonary Pharmacology & Therapeutics. 18:229-234
This double-blind, double-dummy, crossover study evaluated the tolerability of high-dose formoterol and salbutamol. Sixteen adults with mild/moderate persistent asthma (FEV1or = 70% predicted) were randomized to receive either formoterol 36 microg th
Autor:
Ann Horowitz, Martine Hubert, Suzanne K. Swan, James F. McLeod, Silke Appel-Dingemanse, Stuart Osborne, Latifa Alladina, Larry Lambrecht, Honghui Zhou
Publikováno v:
The Journal of Clinical Pharmacology. 43:359-364
Tegaserod (HTF 919), a selective 5-HT4 receptor partial agonist with promotile activity throughout the gastrointestinal tract, is in development for the treatment of irritable bowel syndrome. In an open-label, parallel-group study, the pharmacokineti
Autor:
Vikas Mahavni, Richard E. Buller, Stan Petrauskas, R. Kreienberg, Dennis J. Slamon, Mark D. Pegram, Jo Ann Horowitz, Beth Y. Karlan, Ingo B Runnebaum, Mark S. Shahin
Publikováno v:
Cancer Gene Therapy. 9:567-572
Objective: We have previously reported the safety, efficient gene transfer, and favorable CA125 responses of individuals with recurrent ovarian cancer treated by p53 gene replacement with the adenoviral vector SCH 58500. The purpose of the present in
Autor:
James F. McLeod, James E. Foley, Steven E. Kahn, Damayanthi Devineni, Chyi-Hung Hsu, Monica Ligueros-Saylan, Ann Horowitz, William Howell, Brenda Montgomery
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 86:5824-5829
Insulin secretion is impaired in type 2 diabetes with the early response being essentially absent. The loss of this early insulin secretion is hypothesized to be important in the deterioration of glucose tolerance. To determine whether enhancement of